NYSE: PRGO

PERRIGO Co plc

CIK 0001585364 · Pharmaceutical Preparations

Large Revenue $4.3B Assets $8.0B as of Jul 19, 2026

Perrigo Company plc was incorporated under the laws of Ireland on June 28, 2013 and became the successor registrant of Perrigo Company, a Michigan corporation, on December 18, 2013 in connection with the acquisition of Elan Corporation, plc ("Elan"). Unless the context requires otherwise, the terms… About this business →

Each report below shows a 3-bullet preview. Free accounts read 3 full reports a month — narrative summary, section diffs, and EDGAR-cited quotes.

Sign up free

Want to see a complete report first? Today's free report (THRM 10-Q) is open in full — no account needed.

8-K Filed Jul 6, 2026 · Period ending Jun 29, 2026

Perrigo reinstates executive severance policy during CEO transition period

3 material changes detected. Sign up free to read the summary.

8-K Filed Jun 30, 2026 · Period ending Jun 30, 2026

Perrigo expands Board to 10, adds consumer products and retail veterans

3 material changes detected. Sign up free to read the summary.

Partner

Trade PRGO commission-free

Open an account, get a free stock.

Sign up

Investing involves risk. Free stock terms apply.

8-K Filed Jun 8, 2026 · Period ending Jun 7, 2026 Red flag

Perrigo CEO resigns immediately after board finds conduct violated company values

4 material changes detected. Sign up free to read the summary.

10-Q Filed May 6, 2026 · Period ending Mar 28, 2026 Red flag

Perrigo posts $331M goodwill impairment, 7% revenue decline as restructuring accelerates

5 material changes detected. Sign up free to read the summary.

8-K Filed May 6, 2026 · Period ending May 6, 2026 Critical

Perrigo reports Q1 2026 earnings with impairment charges, debt loss, and infant formula under review

4 material changes detected. Sign up free to read the summary.

8-K Filed May 5, 2026 · Period ending Apr 30, 2026

Perrigo shareholders approve new 2026 equity compensation plan at annual meeting

3 material changes detected. Sign up free to read the summary.

8-K Filed Apr 30, 2026 · Period ending Apr 30, 2026

Perrigo completes €305.6M sale of Dermacosmetics Business to Karo Healthcare

3 material changes detected. Sign up free to read the summary.

10-K Filed Feb 26, 2026 · Period ending Dec 31, 2025

Summary not yet generated.

10-Q Filed Nov 5, 2025 · Period ending Sep 27, 2025

Summary not yet generated.

10-Q Filed May 7, 2025 · Period ending Mar 29, 2025

Summary not yet generated.

10-K Filed Feb 28, 2025 · Period ending Dec 31, 2024

Summary not yet generated.

Latest financial statements

From 10-Q filed May 6, 2026 (period ending Mar 28, 2026). SEC XBRL (companyfacts) — not generated by the model.

SEC XBRL

Consolidated Statements of Operations (Unaudited)

Description Q1 ended Mar 28, 2026 Q1 ended Mar 29, 2025
Revenue:
Total revenue / net sales 969.2 1,044
Cost of revenue / cost of sales 643.7 651.6
Gross profit 325.5 392.3
Operating expenses:
Sales and marketing 129.7 146.2
Research and development 24.6 26.7
General and administrative 115.0 112.2
Total operating expenses 697.8 345.4
Operating income (372.3) 46.9
Other income/(expense), net 6.0 0.4
Income before income taxes (408.5) 8.3
Income tax expense/(benefit) (18.7) 8.2
Net income (398.6) (6.4)
Basic earnings per share (2.87) (0.05)
Diluted earnings per share (2.87) (0.05)

Consolidated Balance Sheets (Unaudited)

Description Mar 28, 2026 Mar 29, 2025
Current assets:
Cash and equivalents 409.9
Accounts receivable, net 697.1 716.8
Inventories 1,121 1,155
Prepaid expenses and other current assets 272.2 229.0
Other current assets 621.7 22.3
Total current assets 2,712 2,533
Property, plant and equipment, net 877.7 913.2
Operating lease right-of-use assets, net 162.3 170.1
Finite-lived intangible assets, net 2,259 2,457
Identifiable intangible assets, net 4,578 4,656
Goodwill 1,702 3,375
Deferred income taxes and other assets 4.7 5.4
Other long-term assets (4,313) (4,350)
TOTAL ASSETS 7,983 9,760
Current liabilities:
Current portion of long-term debt 11.4 36.2
Accounts payable 434.8 502.3
Current portion of operating lease liabilities 26.1 27.5
Accrued liabilities 253.8
Income taxes payable 28.6 14.4
Other current liabilities 496.7 239.6
Total current liabilities 997.6 1,074
Long-term debt 3,621 3,591
Operating lease liabilities 146.7 149.9
Deferred income taxes and other liabilities 153.5 189.2
Other long-term liabilities 565.6 391.6
Total liabilities 5,484 5,396
Shareholders' equity:
Common stock 6,578 6,693
Accumulated other comprehensive income (loss) (3.0) (70.4)
Retained earnings (deficit) (4,076) (2,258)
Total shareholders' equity 2,499 4,364
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY 7,983 9,760

Consolidated Statements of Cash Flows (Unaudited)

Description Q1 ended Mar 28, 2026 Q1 ended Mar 29, 2025
Operating Activities:
Net cash from operating activities (113.6) (64.5)
Investing Activities:
Net cash from investing activities (12.4) (25.7)
Financing Activities:
Net cash from financing activities (45.3) (61.8)
Net increase/(decrease) in cash (174.4) (141.7)

Amounts in millions USD; EPS as reported. Line labels are presentation-friendly mappings of filer XBRL tags — not a re-audit of the full statements. Use EDGAR for interactive notes and detail. Interactive statements & notes on EDGAR ↗

View AI report for this filing

About PERRIGO Co plc

Source: Item 1 (Business) from the 10-K filed February 26, 2026. Description as filed by the company with the SEC.

ITEM 1. BUSINESS

Perrigo Company plc was incorporated under the laws of Ireland on June 28, 2013 and became the successor registrant of Perrigo Company, a Michigan corporation, on December 18, 2013 in connection with the acquisition of Elan Corporation, plc ("Elan"). Unless the context requires otherwise, the terms "Perrigo," the "Company," "we," "our," "us," and similar pronouns used herein refer to Perrigo Company plc, its subsidiaries, and all predecessors of Perrigo Company plc and its subsidiaries.

WHO WE ARE

Perrigo is a leading pure-play self-care company with more than a century of providing high-quality health and wellness solutions to meet the evolving needs of consumers. As one of the originators of the over-the-counter ("OTC") self-care market, Perrigo is led by its vision "To Provide The Best Self-Care For Everyone" and its purpose to "Make Lives Better Through Trusted Health and Wellness Solutions, Accessible To All".

Perrigo works to fulfill its vision and purpose as a top-tier consumer self-care company with a focused portfolio based on consumer-led innovation, which meets societal needs for:

•Access: Perrigo's self-care products and solutions enhance the daily lives of millions of families, empowering them to take control of their health and wellness.

•Value: Perrigo delivers value by helping consumers proactively manage their well-being through affordable and effective self-care solutions.

•Reliability: Perrigo ensures the safety and effectiveness of its self-care solutions, best serving its consumers.

Read full description ↓

Perrigo provides access to trusted self-care solutions that can be used without the need to visit a health practitioner for a prescription. Guided by our vision and purpose, our strategic goal is to create sustainable and value accretive growth by 1) delivering consumer preferred brands and innovation, 2) driving category growth with our customers, 3) powering our business with our world-class, quality assured supply chain, including a focus on sustainability with meaningful goals to reduce greenhouse gas emissions, water, and waste, in addition to increasing the recyclability of our packaging, and 4) evolving our global organization to one cohesive operating model. Our unique competency is to deliver health and wellness solutions across multiple price and value tiers that improve access and choice for consumers.

Perrigo's broad offerings are well diversified across several major product categories as well as across geographies, primarily in North America and Europe, with no one product representing more than 5% of total revenue. In North America, Perrigo is the leading store brand private label provider of self-care products in many categories, including upper respiratory, healthy lifestyle and women's health, along with brands including Opill® and Mederma®. In Europe, our portfolio consists primarily of brands, including Compeed®, ellaOne®, Solpadeine®, Jungle Formula®, and ACO®.

Two key initiatives have been fundamental in advancing our self-care strategy — our Supply Chain Reinvention Program, a global supply chain efficiency program, and Project Energize, a global investment and efficiency program. In addition, we continue to invest in other initiatives, including innovation, information systems and tools, and our people to drive consistent and sustainable results.

Perrigo’s unique complementary businesses enable each individually to play a specific reinforcing role, where 1) store brands generate cash for investments into the Company’s key higher margin, higher growth brands, 2) branding and innovation capabilities deliver both brand and store brand demand generation designed to lead to stronger customer partnerships, 3) consumer-led innovation scaled across brands, store brands and geographies, and 4) leveraging global supply chain scale of more molecules at more price points to more consumers driving household penetration.

The Company’s plan to drive cash flow and total shareholder return is anchored behind its ‘Three-S’ plan – ‘Stabilizing’ Consumer Self-Care Americas store brand and infant formula businesses; ‘Streamlining’ the global portfolio, enterprise operating model and Consumer Self-Care International business; and ‘Strengthening’ what is working by prioritizing and increasing investments behind key brands. Further 2025 highlights can be found in